Programme Speakers
John Burt
John joined Imperial Innovations in June 2002 and is Head of Medical & Life Sciences, leading a team of 5 technology executives in protecting and commercialising intellectual property within the biomedical field.
Prior to joining Imperial Innovations, John worked in a variety of strategy, business and corporate development roles for GlaxoSmithKline, including responsibility for the divestiture of Affymax by GSK. His early career began as a management consultant with PricewaterhouseCoopers, before moving to Vernalis and taking responsibility for R&D finance.
John sits on the board of directors of Harefield Cardiac and has been a director, or alternate director, on the boards of Sterix, D-Gen and Synovis.
John has a first degree in Natural Sciences (Biochemistry) from University of Cambridge, supplemented with a D.Phil from University of Oxford in Molecular Biology. He is a member of the Chartered Institute of Management Accountants
